I'm LongbridgeAI, I can summarize articles.Regencell Bioscience rose 4.08% in the after-hours market; Pfizer fell 1.03%, with a trading volume of USD 396,300; Eli Lilly rose 0.02%, with a trading volume of USD 71,700; Novo Nordisk fell 0.25%, with a trading volume of USD 46,800
U.S. Stock Night Market Movements
Regencell Bioscience rose 4.08% in the night market. Based on recent important news:
-
On June 16, Regencell Bioscience conducted a 38-for-1 stock split, resulting in a very low number of circulating shares, driving the stock price to soar.
-
On June 17, Regencell Bioscience pre-market rose 45%, with retail investors flocking in.
-
On June 18, the stock price of Regencell Bioscience skyrocketed, seen as driven by speculation.
Stocks with High Trading Volume in the Industry
Pfizer fell 1.03% in the night market, with a trading volume of $396,300. Based on recent important news:
-
On July 24, Pfizer signed a global exclusive licensing agreement with 3SBio, obtaining the development rights for PD-1/VEGF bispecific antibodies, strengthening its oncology product line, which led to a 1.03% drop in stock price.
-
On July 24, the FDA announced the cessation of production of Pfizer's Glucotrol XL medication, raising market concerns about its future profitability.
-
On July 23, analysts maintained a wait-and-see attitude towards Pfizer, believing that five other stocks had better investment value, affecting investor confidence.
Eli Lilly rose 0.02% in the night market, with a trading volume of $71,700. Based on recent important news:
-
On July 24, Eli Lilly announced that its acquisition deal with Verve would be completed on July 25, which was positively received by the market, pushing the stock price slightly up.
-
On July 24, Eli Lilly will announce its second-quarter financial report on August 7, and investors are optimistic about the upcoming report, supporting the stock price.
-
On July 23, analysts maintained a "Moderate Buy" rating on Eli Lilly but noted that there are better investment options, affecting market confidence.
Novo Nordisk fell 0.25% in the night market. Based on recent important news:
-
On July 22, Novo Nordisk announced that its drug Ozempic® was approved for a new indication in China, which was positively received by the market, but the stock price did not see a significant increase.
-
On July 23, an Indian pharmaceutical company plans to launch a generic version of Novo Nordisk's weight loss drug, which may affect its market share.
-
On July 22, the FDA announced that some insulin products from Novo Nordisk would be discontinued, which could impact the company's revenue